ALLO
Allogene Therapeutics Inc
NASDAQ · Biotechnology
$1.69
+0.06 (+3.68%)
Open$1.66
Previous Close$1.63
Day High$1.75
Day Low$1.63
52W High$3.78
52W Low$0.86
Volume—
Avg Volume7.92M
Market Cap379.79M
P/E Ratio—
EPS$-0.98
SectorBiotechnology
Analyst Ratings
Strong Buy
20 analysts
Price Target
+1,202.4% upside
Current
$1.69
$1.69
Target
$22.01
$22.01
$17.29
$22.01 avg
$30.07
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 52.71M | 52.93M | 41.75M |
| Net Income | 7.77M | 8.17M | 5.40M |
| Profit Margin | 14.7% | 15.4% | 12.9% |
| EBITDA | 12.72M | 14.19M | 11.69M |
| Free Cash Flow | 7.78M | 12.29M | 5.60M |
| Rev Growth | +19.4% | -7.3% | -1.4% |
| Debt/Equity | 1.42 | 1.47 | 1.26 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |